Premium
Clinical and hemodynamic performance of the ACURATE neo bioprosthesis: Looking far and beyond randomized trials
Author(s) -
Franzone Anna,
Esposito Giovanni
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29447
Subject(s) - medicine , randomized controlled trial , hemodynamics , cardiology , clinical trial , surgery
Highlights In elderly patients, TAVR with the ACURATE neo ™ bioprosthesis is associated with good mid to long‐ term clinical outcomes, progressive reduction of PVL severity over time and no warnings of structural valve deterioration or bioprosthetic valve failure. The long‐term echocardiographic performance of the ACURATE neo ™ bioprosthesis in real‐world patients is better than anticipated in randomized trials. Further studies need to clarify longer terms outcomes of TAVR with the ACURATE neo ™ bioprosthesis and technical tips to mitigate the occurrence of moderare or severe PVL.